ArticleGenome medicine2021
Evaluating the transcriptional fidelity of cancer models.
Article in Genome medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies.BMC cancer · 2021Pooled it
- Hierarchical modeling of tumor subtypes in cell lines using large-scale genomic datasets.iScience · 2026Article
- Exceptional treatment responses and molecular markers among 103 colorectal cancer cell lines.Molecular biomedicine · 2026Article
- Patient-derived organoids from metastatic colorectal cancer mirror tumor heterogeneity and predict patient survival and drug sensitivity.Cell reports. Medicine · 2026Article
- Tumor organoids as a revolutionary platform for advancing cancer nanomedicine.Molecular cancer · 2026Review
- Multi-omics evaluation of cell lines as models for metastatic prostate cancer.Communications biology · 2026Article
- Common gene mutations in 103 authenticated colorectal cancer cell lines.Oncogenesis · 2026Article
- Tumor-on-chip's alliance with molecular pathology against metastatic disease.Journal of biomedical science · 2026Review
- Aging represses oncogenic KRAS-driven lung tumorigenesis and alters tumor suppression.Nature aging · 2025Article
- Long-term maintenance of patient-specific characteristics in tumoroids from six cancer indications.Scientific reports · 2025Article
- Biologically relevant integration of transcriptomics profiles from cancer cell lines, patient-derived xenografts, and clinical tumors using deep learning.Science advances · 2025Article
- A New Perspective on Precision Medicine: The Power of Digital Organoids.Biomaterials research · 2025Review
- Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models.Molecular oncology · 2024Article
- Genomic profiling of a multi-lineage and multi-passage patient-derived xenograft biobank reflects heterogeneity of ovarian cancer.Cell reports. Medicine · 2024Article
- Bridging systems biology and tissue engineering: Unleashing the full potential of complex 3DBiophysics reviews · 2024Review
- Evaluating cell culture reliability in pediatric brain tumor primary cells through DNA methylation profiling.NPJ precision oncology · 2024Article
- Closing in on cancer heterogeneity with organoids.Nature methods · 2024Article
- Research progress on the application of organoids in gynecological tumors.Frontiers in pharmacology · 2024Review
- Systems approach for congruence and selection of cancer models towards precision medicine.PLoS computational biology · 2024Article
- Systematic transcriptional analysis of human cell lines for gene expression landscape and tumor representation.Nature communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCancer researchers use cell lines, patient-derived xenografts, engineered mice, and tumoroids as models to investigate tumor biology and to identify therapies. The generalizability and power of a model derive from the fidelity with which it represents the tumor type under investigation; however, the extent to which this is true is often unclear. The preponderance of models and the ability to readily generate new ones has created a demand for tools that can measure the extent and ways in which cancer models resemble or diverge from native tumors.
methodsWe developed a machine learning-based computational tool, CancerCellNet, that measures the similarity of cancer models to 22 naturally occurring tumor types and 36 subtypes, in a platform and species agnostic manner. We applied this tool to 657 cancer cell lines, 415 patient-derived xenografts, 26 distinct genetically engineered mouse models, and 131 tumoroids. We validated CancerCellNet by application to independent data, and we tested several predictions with immunofluorescence.
resultsWe have documented the cancer models with the greatest transcriptional fidelity to natural tumors, we have identified cancers underserved by adequate models, and we have found models with annotations that do not match their classification. By comparing models across modalities, we report that, on average, genetically engineered mice and tumoroids have higher transcriptional fidelity than patient-derived xenografts and cell lines in four out of five tumor types. However, several patient-derived xenografts and tumoroids have classification scores that are on par with native tumors, highlighting both their potential as faithful model classes and their heterogeneity.
conclusionsCancerCellNet enables the rapid assessment of transcriptional fidelity of tumor models. We have made CancerCellNet available as a freely downloadable R package ( https://github.com/pcahan1/cancerCellNet ) and as a web application ( http://www.cahanlab.org/resources/cancerCellNet_web ) that can be applied to new cancer models that allows for direct comparison to the cancer models evaluated here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.